REPOSITIONING INTELLIGENCE — EVIDENCE REPORT
============================================
Generated: Nov 12, 2026, 11:53 PM UTC

DISCLAIMER: This report is for research and informational use only.
It is NOT medical advice, diagnosis, or treatment guidance.

DRUG–DISEASE PAIRING
--------------------
Drug:     Hydroxychloroquine
Disease:  COVID-19
Target:   Lysosomal pathway

EVIDENCE GRADE: Insufficient Evidence
Confidence Score: 12%
Evidence Level: Level 1 (negative RCTs)
Trial Phase: Multiple Phase III (negative)

MECHANISM
---------
Proposed antiviral and immunomodulatory effects via lysosomal pH and autophagy.

OUTCOMES
--------
Large RCTs (RECOVERY, SOLIDARITY) showed no mortality benefit; not recommended.

AI SUMMARY (generated March 15, 2026)
-----------
Despite early enthusiasm, hydroxychloroquine lacks efficacy for COVID-19. RECOVERY and SOLIDARITY trials demonstrated no benefit; WHO recommends against use. Important negative repurposing example.

KNOWN RISKS
-----------
• Retinopathy with long-term use (requires screening)
• QT prolongation
• Hypoglycemia
• GI upset

CITATIONS
---------
[PUBMED] 33031652: Repurposed antiviral drugs for COVID-19 (SOLIDARITY)
  https://pubmed.ncbi.nlm.nih.gov/33031652/

[CLINICALTRIALS] NCT04332991: SOLIDARITY trial
  https://clinicaltrials.gov/study/NCT04332991

PUBMED IDs: 33031652
CLINICAL TRIAL IDs: NCT04381936, NCT04332991

LAST VERIFIED: June 29, 2026
LAST UPDATED:  June 29, 2026
REVIEW STAGE:  published

---
Repositioning Intelligence Platform · Research Mode